(Deudextromethorphan hydrobromide + quinidine sulfate) is a Small Molecule owned by Avanir Pharmaceuticals, and is involved in 14 clinical trials, of which 10 were completed, and 4 are ongoing.

Deuterated dextromethorphan is a modified dextromethorphan with deuterium in its specific molecular positions for the treatment of neurological and psychiatric disorders. Dextromethorphan (DM) is a sigma-1 receptor agonist, an uncompetitive NMDA receptor antagonist, serotonin and norepinephrine reuptake inhibitor and neuronal nicotinic receptor antagonist. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. It is an agonist to the opioid sigma 1.

The revenue for (Deudextromethorphan hydrobromide + quinidine sulfate) is expected to reach a total of $3.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Deudextromethorphan hydrobromide + quinidine sulfate) NPV Report.

(Deudextromethorphan hydrobromide + quinidine sulfate) is currently owned by Avanir Pharmaceuticals. Otsuka Holdings is the other company associated in development or marketing of (Deudextromethorphan hydrobromide + quinidine sulfate).

(Deudextromethorphan hydrobromide + quinidine sulfate) Overview

AVP-786 is under development for the treatment of residual schizophrenia symptoms, agitation associated with dementia of the Alzheimer's type. It is a next-generation Nuedexta. The drug candidate is administered as capsule through oral route. It consists of a combination of deuterium modified dextromethorphan hydrobromide and ultra-low dose quinidine sulfate. It is an NMDA receptor antagonist and acts as a non-competitive channel blocker. The drug candidate is developed using DCE Platform (Deuterated Chemical Entity Platform) technology that produces several deuterium-modified dextromethorphan compounds. It was under development for intermittent explosive disorder, levodopa-induced dyskinesia in Parkinson's disease, traumatic brain injury, treatment resistant major depressive disorder, disinhibition syndrome in patients with neurodegenerative disorders and neuropathic pain.

Otsuka Holdings Overview

Otsuka Holdings (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices and OTC products. It markets its products in North America, Europe, and Asia. Otsuka is headquartered in Chiyoda-ku, Tokyo, Japan.

The company reported revenues of (Yen) JPY1,498,276 million for the fiscal year ended December 2021 (FY2021), an increase of 5.3% over FY2020. In FY2021, the company’s operating margin was 10.3%, compared to an operating margin of 13.8% in FY2020. In FY2021, the company recorded a net margin of 8.4%, compared to a net margin of 10.4% in FY2020. The company reported revenues of JPY451,811 million for the third quarter ended September 2022, an increase of 4.1% over the previous quarter.

Quick View – (Deudextromethorphan hydrobromide + quinidine sulfate)

Report Segments
  • Innovator
Drug Name
  • (Deudextromethorphan hydrobromide + quinidine sulfate)
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.